About
About Veru
Our Scientific Efforts
Management Team
Board of Directors
Scientific Advisory Board
Publications & Meeting Presentations
Pipeline
Cardiometabolic Obesity Drug Program
Cardiometabolic Inflammation Atherosclerosis Program
Investors
Investors
Investor Kit
Press Releases
Stock Information
Financial Information
SEC Filings
Annual Reports
IRS Form 8937
Investor Presentations
Corporate Governance
Letter to Shareholders
Board Committees
Governance Documents
Policy for Director Attendance and for Shareholder Communications with Directors
News
Veru Press Releases
Veru in the News
Contact
Search for:
Annual Reports & Proxy Statements
Investors
Investors
Investor Kit
News & Events
Overview
Press Releases
IR Calendar
Presentations
Email Alerts
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
IRS Form 8937
Stock Data
Quote
Charts
Historical Data
Ratios
SEC Filings
Overview
All SEC Filings
Annual Reports & Proxy Statements
Quarterly Reports
Section 16 Filings
Governance
Overview
Board Committees
Governance Documents
Letter to Shareholders
Policy for Director Attendance and for Shareholder Communications with Directors
2023
2023
Annual Report
2024
Proxy Statement
2024
Form 10-K/A
2022
2022
Annual Report
2023
Proxy Statement
2021
2021
Annual Report
2022
Proxy Statement
2020
2020
Annual Report
2021
Proxy Statement
2019
2019
Annual Report
2018
2018
Annual Report
2017
2017
Annual Report
2016
2016
Annual Report
2015
2015
Annual Report
2014
2014
Annual Report
2013
2013
Annual Report
2012
2012
Annual Report
2011
2011
Annual Report
2010
2010
Annual Report
2009
2009
Annual Report
2008
2008
Annual Report
2007
2007
Annual Report
2006
2006
Annual Report
2005
2005
Annual Report
2004
2004
Annual Report
2003
2003
Annual Report
2002
2002
Annual Report
2001
2001
Annual Report
2000
2000
Annual Report
Email Alerts
Contacts
RSS News Feed
Go to Top
